Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:12
Pelthos Therapeutics Total Liabilities (Quarterly) : 138.86M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 138.86M |
| March 31, 2026 | 126.11M |
| December 31, 2025 | 91.52M |
| September 30, 2025 | 68.18M |
| June 30, 2025 | 5.107M |
| March 31, 2025 | 5.107M |
| September 30, 2024 | 3.567M |
| Date | Value |
|---|---|
| June 30, 2024 | 2.786M |
| March 31, 2024 | 2.901M |
| December 31, 2023 | 6.541M |
| September 30, 2023 | 5.927M |
| June 30, 2023 | 4.983M |
| March 31, 2023 | 4.450M |
| December 31, 2022 | 3.762M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | 825.64M |
| ACADIA Pharmaceuticals, Inc. | 406.66M |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 137.36M |
| Shareholders Equity (Quarterly) | -1.501M |
| Debt to Equity Ratio | -48.71 |
| Current Ratio | 1.982 |
| Net Debt Paydown Yield | -13.44% |